Previous post Next post

Swiss pharma group warns access to new medicine is worsening

Interpharma, the association of research-based pharmaceutical companies in Switzerland, believes that access to innovative medicines is worsening since the US introduced policies to lower drug prices in line with peer countries. A survey of member companies has shown that pharmaceutical manufacturers no longer consider themselves able, under the current framework, to launch new therapies in Switzerland in a timely manner without jeopardising prices in the US, Interpharma announced on Thursday. Between January 2025 and June 2026, Interpharma’s members had not submitted seven out of a total of 22 new innovative medicines for inclusion on the Specialities List, which is the list of medicines reimbursed by insurance. In the case of three others, they had even decided not to submit them to the Swiss medicines agency Swissmedic for authorisation. + Drugmakers reassess Europe as Trump overhauls drug-pricing rules According to Interpharma, this underscores the US administration’s policy ... Full story here Are you the author?
About Swissinfo
Swissinfo
SWI swissinfo.ch – the international service of the Swiss Broadcasting Corporation (SBC). Since 1999, swissinfo.ch has fulfilled the federal government’s mandate to distribute information about Switzerland internationally, supplementing the online offerings of the radio and television stations of the SBC. Today, the international service is directed above all at an international audience interested in Switzerland, as well as at Swiss citizens living abroad.
Previous post See more for 3.) Swissinfo Business and Economy Next post
Tags: ,

Permanent link to this article: https://snbchf.com/2026/08/swiss-pharma-warns-access-new-medicine-worsening/

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

This site uses Akismet to reduce spam. Learn how your comment data is processed.